Physician profile
Michelle E Cooke
NPI 1568759264
$3,090.38
in general payments reported to CMS, 2019-2025
31 companies · $44.03 in 2025
The $44.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $482 · 2021: $300 · 2022: $840 · 2023: $256 · 2024: $89.90 · 2025: $44.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $680.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $339.66 | 2019-2023 | Fasenra |
| Sanofi-Aventis U.S. LLC | $280.96 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.48 | 2019-2022 | |
| Lilly USA, LLC | $182.96 | 2019-2023 | Mounjaro |
| Astellas Pharma US INC | $177.28 | 2019-2020 | |
| Amgen INC. | $131.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $121.29 | 2019-2020 | |
| Abbvie INC. | $113.99 | 2021-2024 | Vraylar, Viberzi, Linzess |
| Abbott Laboratories | $91.71 | 2020-2022 | |
| Viiv Healthcare Company | $89.07 | 2023-2024 | Apretude, Rukobia, Dovato |
| Pfizer INC. | $80.25 | 2019-2022 | |
| Theratechnologies INC. | $67.96 | 2023 | Egrifta, Trogarzo |
| Exact Sciences Corporation | $54.77 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $42.34 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.65 | 2021-2022 | |
| Gilead Sciences, INC. | $39.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $37.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $35.88 | 2021-2025 | Benlysta |
| Janssen Pharmaceuticals, INC | $27.88 | 2020 | |
| Allergan, INC. | $27.09 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $26.65 | 2019-2020 | |
| Boston Scientific Corporation | $25.78 | 2025 | General - Pain Management |
| Amarin Pharma, INC. | $23.32 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.98 | 2022 | |
| Duchesnay USA Incorporated | $21.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.42 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.13 | 2022 | |
| Phadia US INC. | $17.60 | 2019 | |
| Daiichi Sankyo INC. | $17.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Cooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.